in TF-Expressing Solid Tumors | Sutro Biopharma, Inc.

Sutro Biopharma Announces First Cohort of Patients Dosed in Phase 1 Trial of STRO-004, a Next-Generation Tissue Factor ADC, in TF-Expressing Solid Tumors

Sutro Biopharma Announces First Cohort of Patients Dosed in Phase 1 Trial of STRO-004, a Next-Generation Tissue Factor ADC, in TF-Expressing Solid Tumors – Initial clinical data expected mid-2026 – South San Francisco, Calif. — December 3, 2025 — Sutro Biopharma,...